SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Syndax Pharmaceuticals Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$13.09+0.19 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- –
- Dividend yield
- –
Syndax Pharmaceuticals Inc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $54.70M | $48.92M | – | $32.01M | $28.60M | $20.04M | – | $0 | $0 | – | 75.1% | +91.3% |
| Collaboration revenue | $18.09M | $15.94M | $19.39M | $13.86M | $9.36M | $0 | $0 | $0 | $0 | – | 24.9% | +93.3% |
| Milestone revenue | – | – | $5.14M | $0 | $0 | – | $0 | $12.50M | $3.50M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Syndax Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.